Announcements Trials
Browse Landscape

Phase

Phase 4 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2NET 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Pituitary Neoplasms 7Prolactinoma 5Polycystic Ovary Syndrome 3Pituitary ACTH Hypersecretion 3Hyperprolactinemia 2Acromegaly 2Recurrence 1Prostatic Neoplasms 1Prolactin Deficiency, Isolated 1Ovarian Hyperstimulation Syndrome 1Neuroendocrine Tumors 1Neoplasms 1Melanoma 1Dumping Syndrome 1Breast Neoplasms 1Brain Neoplasms 1Adrenocortical Hyperfunction 1Adenoma 1ACTH-Secreting Pituitary Adenoma 1

Interventions

pasireotide 5lanreotide 4Octreotide 4pegvisomant 2Cabergoline 2Transcranial Magnetic Stimulation 1Solutions 1Radiosurgery 1Injections 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Acromegaly × Cabergoline × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT00376064 2017-03-06

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Novartis

Phase 4 Completed
20 enrolled
CNSEndocrine

Acromegaly, Brain Neoplasms, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡